Part 1 of this two-part series on injection techniques describes the evidence base and procedure for administering an intramuscular injection. This updates an article previously published in 2018.

A new intramuscular (IM) injection option of Biogen’s Plegridy (peginterferon beta-1a) has been approved by the European Commission for the treatment of relapsing-remitting multiple sclerosis (MS).

Observations on this point fail to carry conviction, however, because inadequate methods are used for ascertaining the facts. A method for the bioassay of diuretic agents in ambulant patients with ...

Part 1 of this two-part series on injection techniques describes the evidence base and procedure for administering an intramuscular injection Subscribe today to access over 6,000 peer-reviewed ...